842 related articles for article (PubMed ID: 18070166)
1. Expansion of circulating Foxp3+)D25bright CD4+ T cells during specific venom immunotherapy.
Pereira-Santos MC; Baptista AP; Melo A; Alves RR; Soares RS; Pedro E; Pereira-Barbosa M; Victorino RM; Sousa AE
Clin Exp Allergy; 2008 Feb; 38(2):291-7. PubMed ID: 18070166
[TBL] [Abstract][Full Text] [Related]
2. Ultra-rush venom immunotherapy induces differential T cell activation and regulatory patterns according to the severity of allergy.
Mamessier E; Birnbaum J; Dupuy P; Vervloet D; Magnan A
Clin Exp Allergy; 2006 Jun; 36(6):704-13. PubMed ID: 16776670
[TBL] [Abstract][Full Text] [Related]
3. Immunoblot studies in allergic patients to hymenoptera venom before and during immunotherapy.
Pereira Santos MC; Pedro E; Spínola Santos A; Branco Ferreira M; Palma Carlos ML; Palma Carlos AG
Eur Ann Allergy Clin Immunol; 2005 Sep; 37(7):273-8. PubMed ID: 16285233
[TBL] [Abstract][Full Text] [Related]
4. Insect venom immunotherapy induces interleukin-10 production and a Th2-to-Th1 shift, and changes surface marker expression in venom-allergic subjects.
Bellinghausen I; Metz G; Enk AH; Christmann S; Knop J; Saloga J
Eur J Immunol; 1997 May; 27(5):1131-9. PubMed ID: 9174602
[TBL] [Abstract][Full Text] [Related]
5. Rush hymenoptera venom immunotherapy is efficacious and safe.
Pasaoglu G; Sin BA; Misirligil Z
J Investig Allergol Clin Immunol; 2006; 16(4):232-8. PubMed ID: 16889280
[TBL] [Abstract][Full Text] [Related]
6. Serum concentration of baseline mast cell tryptase: evidence for a decline during long-term immunotherapy for Hymenoptera venom allergy.
Dugas-Breit S; Przybilla B; Dugas M; Arnold A; Pfundstein G; Küchenhoff H; Ruëff F
Clin Exp Allergy; 2010 Apr; 40(4):643-9. PubMed ID: 20100187
[TBL] [Abstract][Full Text] [Related]
7. Regulatory T cells in children undergoing rush venom immunotherapy.
Ajduk J; Turkalj M; Gagro A
Allergy Asthma Proc; 2012; 33(6):525-30. PubMed ID: 23394512
[TBL] [Abstract][Full Text] [Related]
8. Humoral immunological response in patients with venom allergy during specific immunotherapy.
Szymański W; Chyrek-Borowska S
Rocz Akad Med Bialymst; 1995; 40(2):376-82. PubMed ID: 8834621
[TBL] [Abstract][Full Text] [Related]
9. [Immunotherapy against hymenoptera venom: report of ten patients].
Guzmán M MA; Salinas L J; Toche P P; Marinovic M MA; Gallardo O AM
Rev Med Chil; 2007 Dec; 135(12):1566-71. PubMed ID: 18357358
[TBL] [Abstract][Full Text] [Related]
10. Basophil sensitivity in patients not responding to venom immunotherapy.
Peternelj A; Silar M; Erzen R; Kosnik M; Korosec P
Int Arch Allergy Immunol; 2008; 146(3):248-54. PubMed ID: 18270492
[TBL] [Abstract][Full Text] [Related]
11. Agreement of skin test with IL-4 production and CD40L expression by T cells upon immunotherapy of subjects with systemic reactions to Hymenoptera stings.
Urra JM; Cabrera CM; Alfaya T; Feo-Brito F
Mol Immunol; 2016 Feb; 70():134-9. PubMed ID: 26774053
[TBL] [Abstract][Full Text] [Related]
12. Patients still reacting to a sting challenge while receiving conventional Hymenoptera venom immunotherapy are protected by increased venom doses.
Ruëff F; Wenderoth A; Przybilla B
J Allergy Clin Immunol; 2001 Dec; 108(6):1027-32. PubMed ID: 11742283
[TBL] [Abstract][Full Text] [Related]
13. Hymenoptera venom allergy.
Przybilla B; Ruëff F
J Dtsch Dermatol Ges; 2010 Feb; 8(2):114-27; quiz 128-30. PubMed ID: 19751222
[TBL] [Abstract][Full Text] [Related]
14. Specific ultrarush desensitization in Hymenoptera venom-allergic patients.
Schiavino D; Nucera E; Pollastrini E; De Pasquale T; Buonomo A; Bartolozzi F; Lombardo C; Roncallo C; Patriarca G
Ann Allergy Asthma Immunol; 2004 Apr; 92(4):409-13. PubMed ID: 15104191
[TBL] [Abstract][Full Text] [Related]
15. Three days rush venom immunotherapy in bee allergy: safe, inexpensive and instantaneously effective.
Goldberg A; Yogev A; Confino-Cohen R
Int Arch Allergy Immunol; 2011; 156(1):90-8. PubMed ID: 21447964
[TBL] [Abstract][Full Text] [Related]
16. Surface membrane antigen alteration on blood basophils in patients with Hymenoptera venom allergy under immunotherapy.
Siegmund R; Vogelsang H; Machnik A; Herrmann D
J Allergy Clin Immunol; 2000 Dec; 106(6):1190-5. PubMed ID: 11112905
[TBL] [Abstract][Full Text] [Related]
17. Safety of angiotensin-converting enzyme inhibitors while receiving venom immunotherapy.
White KM; England RW
Ann Allergy Asthma Immunol; 2008 Oct; 101(4):426-30. PubMed ID: 18939733
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of immunotherapy to wasp and bee venom.
Ozdemir C; Kucuksezer UC; Akdis M; Akdis CA
Clin Exp Allergy; 2011 Sep; 41(9):1226-34. PubMed ID: 21729181
[TBL] [Abstract][Full Text] [Related]
19. Flow-assisted quantification of in vitro activated basophils in the diagnosis of wasp venom allergy and follow-up of wasp venom immunotherapy.
Ebo DG; Hagendorens MM; Schuerwegh AJ; Beirens LM; Bridts CH; De Clerck LS; Stevens WJ
Cytometry B Clin Cytom; 2007 May; 72(3):196-203. PubMed ID: 17111386
[TBL] [Abstract][Full Text] [Related]
20. Skin-infiltrating T cells and cytokine expression in Icelandic horses affected with insect bite hypersensitivity: a possible role for regulatory T cells.
Heimann M; Janda J; Sigurdardottir OG; Svansson V; Klukowska J; von Tscharner C; Doherr M; Broström H; Andersson LS; Einarsson S; Marti E; Torsteinsdottir S
Vet Immunol Immunopathol; 2011 Mar; 140(1-2):63-74. PubMed ID: 21168921
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]